ado-trastuzumab emtansine (Kadcyla)
ado-trastuzumab emtansine is an FDA-licensed reference biologic from Genentech, Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2013
Reference approved
Reference product
Kadcyla ado-trastuzumab emtansine
Genentech, Inc.
- Approved
- Feb 22, 2013
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for ado-trastuzumab emtansine, in chronological order.
Reference approval
Approval date of the reference ado-trastuzumab emtansine product.
13 yr 6 mo ago
Frequently asked questions
Are there biosimilars approved for ado-trastuzumab emtansine (Kadcyla)?
No 351(k) biosimilars or interchangeable biosimilars referencing ado-trastuzumab emtansine are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.